Core Viewpoint - The article emphasizes the importance of value investing and highlights OraSure Technologies (OSUR) as a strong value stock based on its metrics and rankings [3][6]. Value Investing - Value investing is a popular strategy that focuses on identifying undervalued stocks using fundamental analysis and established metrics [2]. - The Zacks Rank system is utilized to find winning stocks, with a specific focus on earnings estimates and revisions [1]. Company Metrics - OraSure Technologies (OSUR) has a Zacks Rank of 1 (Strong Buy) and an "A" grade for Value, indicating it is among the best value stocks currently available [3]. - OSUR's Price-to-Sales (P/S) ratio is 1.29, which is lower than the industry average of 1.59, suggesting it may be undervalued [4]. - The Price-to-Cash Flow (P/CF) ratio for OSUR is 12.54, significantly lower than the industry average of 39.25, indicating a favorable valuation based on cash flow [5]. - Over the past 12 months, OSUR's P/CF has fluctuated between 6.11 and 14.08, with a median of 8.39, further supporting its undervaluation [5][6].

Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions [1] - The company aims to transform health through actionable insights and improve access, quality, and value of healthcare with innovative testing solutions [3] - OraSure's product portfolio includes rapid diagnostic tests and sample collection devices, sold globally to various healthcare entities [3] Upcoming Event - OraSure's management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference [1] - The presentation is scheduled for January 16, 2025, at 9:00 a.m. PT [1] - A live webcast and replay of the presentation will be available on OraSure's investor relations website [2]

Core Viewpoint - The article emphasizes the importance of value investing and highlights OraSure Technologies (OSUR) as a strong value stock based on various financial metrics [2][3][6] Company Analysis - OraSure Technologies (OSUR) currently holds a Zacks Rank of 2 (Buy) and has a Value grade of A, indicating it is considered a strong value stock [3] - The company's price-to-sales (P/S) ratio is 1.24, which is lower than the industry average of 1.72, suggesting that OSUR may be undervalued [4] - OSUR's price-to-cash flow (P/CF) ratio stands at 11.81, significantly lower than the industry's average of 37.04, indicating a favorable cash outlook for the company [5] - Over the past 52 weeks, OSUR's P/CF has fluctuated between 6.11 and 14.08, with a median of 8.27, further supporting the notion of its current undervaluation [5][6] Industry Insights - Value investing remains a preferred strategy for identifying strong stocks across various market conditions, relying on traditional valuation metrics [2] - The P/S ratio is favored by some investors as it is less susceptible to manipulation compared to earnings figures, making it a potentially more reliable performance indicator [4]

Core Insights - OraSure Technologies, Inc. has received FDA approval for a labeling change to the OraQuick® HIV Self-Test, expanding its use to adolescents aged 14 and older, previously limited to those 17 and older [1] - The change aims to increase access to HIV testing for young people, addressing a significant gap as 19% of new HIV diagnoses in the U.S. are among individuals aged 13 to 24, with only 6% of high school students having ever been tested [2][3] Company Overview - OraSure Technologies is a leader in point-of-need and home diagnostic tests, focusing on improving access to healthcare through innovative testing solutions [1][4] - The company has been committed to providing consumers with critical information and connections to care since the launch of the OraQuick® HIV Self-Test in 2012, which includes educational materials and care linkage information [3][4] Industry Context - Increasing access to HIV testing options is crucial for ending the HIV epidemic, particularly for adolescents who test positive, emphasizing the need for early connection to care [3] - The approval of the OraQuick® HIV Self-Test for younger populations is a strategic move to combat the stigma surrounding HIV testing and improve awareness among adolescents [3]

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older. According to the most recent data available from the Centers for Disease Control & Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young peopl ...

OraSure Technologies, Inc. (OSUR) recently announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.This acquisition enhances OraSure’s innovation pipeline by incorporating Sherlock Biosciences’ molecular diagnostics platform. This platform delivers rapid results with high sensitivity and specificity in a disposable format ideal for over-the-counter use.Likely Trend of OSUR Stock Following the NewsFollowing th ...

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with s ...

I worked for many years at an investment firm where I invested across public and private market opportunities. I underwrote fund managers, as well as individual securities. I left the firm to pursue an MBA from a Top-20 US B School. At school, I won the nation's premier stock pitching competition and was portfolio manager for the school's Consumer sector investments. During that time, I interned at a multi-family office and a hedge fund. I became adept at using Bloomberg and Factset for research. On top of ...

BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Resp ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics an ...